Mast cell tumours (MCTs) are the most common cutaneous malignancies in dogs having often a poor prognosis.
Masivet® is an effective, highly-specific drug, targeting key biological pathways crucial for MCT development and growth.
Masivet® was approved in 2008 by the European Medicine Agency (EMA) in veterinary medicine for the treatment of dog non-resectable MCTs (grade 2 or 3) with presence of a mutated form of the receptor protein c-kit.
In 2018, AB Science celebrated the 10th anniversary of the marketing authorization of Masivet®. Since its approval, Masivet has been used with success as a targeted approach to cancer management in veterinary medicine and tens of thousands of cases have been treated successfully with Masivet®. Veterinary clinics favor the excellent possibilities of case-management of high grade MCTs in the everyday practice with the use of Masivet®.